AI reads chest X-Rays to catch lung cancer earlier

NCT ID NCT06044454

Ongoing Diagnosis Sponsor: NHS Greater Glasgow and Clyde Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing an artificial intelligence software called qXR that automatically analyzes chest X-rays to spot signs of lung cancer. The goal is to see if using AI to prioritize which X-rays need urgent review can speed up the time it takes for patients to get a follow-up CT scan or a final decision. The study involves 60,000 adults in Scotland whose chest X-rays are taken as part of routine care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: qXR (artificial intelligence software for chest X-ray analysis)
What this could lead to: If successful, this AI could help doctors find lung cancer earlier by flagging suspicious chest X-rays faster, potentially improving survival rates.
What could go wrong: This is a large but early-stage real-world test. The AI may not speed up diagnosis as hoped, or could miss some cancers. It is not a treatment itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Glasgow Royal Infirmary (North Sector)

Glasgow, United Kingdom
NHS Greater Glasgow and Clyde

Glasgow, United Kingdom
Queen Elizabeth University Hosp (South Sector)

Glasgow, United Kingdom
The Royal Alexandra Hospital (Clyde Sector)

Paisley, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.